Rosiglitazone increases testosterone in hypogonadal type 2 diabetic men.
Cohen
Paul
P
D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007006:Hypogonadism / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D009765:Obesity / Q000503:physiopathology; D000077154:Rosiglitazone; D013739:Testosterone / Q000097:blood*; D045162:Thiazolidinediones / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone; D013739:Testosterone